Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine

Cancer Chemother Pharmacol. 1984;13(3):191-4. doi: 10.1007/BF00269027.

Abstract

The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to the cytotoxic effects of 5-AZA-CdR than cells in the plateau phase of growth. These results indicate that 5-AZA-CdR produces a preferential kill of cells in the S phase of the cell cycle. 5-AZA-CdR did not block the cell cycle progression of cells into S phase. The survival curve of EMT6 cells exposed to 5-AZA-CdR suggests that the cytotoxic action of this analogue is not self-limiting. The mutagenic activity of 5-AZA-CdR was investigated using induction of 6-thioguanine resistance in Chinese hamster ovary cells. 5-AZA-CdR was not a detectable mutagen in this assay system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azacitidine / analogs & derivatives*
  • Azacitidine / pharmacology
  • Azacitidine / toxicity
  • Cell Cycle / drug effects*
  • Cell Line
  • Cell Survival / drug effects
  • DNA Replication / drug effects
  • Decitabine
  • Female
  • Mammary Neoplasms, Experimental
  • Mice
  • Mutation / drug effects
  • Thioguanine / pharmacology

Substances

  • Decitabine
  • Thioguanine
  • Azacitidine